Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/4/2018
SIETES contiene 92261 citas

 
 
 1 a 20 de 39 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Go AS, Singer DE, Toh S, Cheetham TC, Reichman ME, Graham DJ, Southworth MR, Zhang R, Izem R, Goulding MR, Houstoun M, Mott K, Sung SH, Gagne JJ. Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice: a retrospective cohort study. Ann Intern Med 2017;167:845-54. [Ref.ID 102196]
2.Tiene citas relacionadas Cita con resumen
Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breidthardt G, Singer DE, Mahaffey KW, Hankey GJ, Berkowtitz SD, Nessel CC, Fox KAA, Califf RM, Piccini JP, Patel MR, ROCKET AF Steering Committee and Investigators. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Lancet 2015;385:2363-70. [Ref.ID 99291]
3.Tiene citas relacionadas Cita con resumen
Singer DE, Ezekowitz MD. Adding rigor to stroke risk prediction in atrial fibrillation. J Am Coll Cardiol 2015;65:233-5. [Ref.ID 99045]
4. Cita con resumen
Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, Patel MR, Berkowitz SD, Becker RC, Halperin JL, Singer DE, Califf RM, Fox KAA, Breithardt G, Hacke W. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med 2013;158:861-8. [Ref.ID 95680]
5.Tiene citas relacionadas Cita con resumen
Gomes T, Redelmeier DA, Juurlink DN, O'Connell JJ, Porneala BC, Stringfellow EJ, Orav EJ, Singer DE, Rigotti NA. Opioid dose and risk of road trauma in Canada: a population-based study. JAMA Intern Med 2013;173:196-201. [Ref.ID 94939]
7. Cita con resumen
Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. New risk scheme to predict warfarin-associated hemorrhage. The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study . J Am Coll Cardiol 2011;58:395-401. [Ref.ID 91253]
8.Tiene citas relacionadas Cita con resumen
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithard G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JP, Berkowitz SD, Fox KAA, Califf RM, for the ROCKET AF investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91. [Ref.ID 90982]
9.Tiene citas relacionadas
Singer DE, Fang MC, Go AS. The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation. Arch Intern Med 2009;169:2032. [Ref.ID 87129]
10.Tiene citas relacionadas Cita con resumen
Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009;151:297-305. [Ref.ID 86705]
11.Tiene citas relacionadas
Go AS, Singer DE. Stroke prevention in atrial fibrillation: another step sideways. Lancet 2008;371:278-80. [Ref.ID 82042]
12. Cita con resumen
Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, Singer DE. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. The American Journal of Medicine 2007;120:700-5. [Ref.ID 78282]
13.
Grant RW, O'Leary KM, Weilburg JB, Singer DE, Meigs JB. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 2004;164:2343-8. [Ref.ID 71994]
14. Cita con resumen
Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004;141:745-52. [Ref.ID 71979]
15.
Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880-4. [Ref.ID 69942]
16.
Fang MC, Stafford RS, Ruskin J N, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004;164:55-60. [Ref.ID 68688]
17. Cita con resumen
Go AS, Hylek EM, Chang Y, Phillips K A, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice?. JAMA 2003;290:2685-92. [Ref.ID 68223]
18.Tiene citas relacionadas
Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JÇV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26. [Ref.ID 67411]
19.
Hylek EM, Regan S, Henault LE, Gardner M, Chan AT, Singer DE, Barry MJ. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med 2003;163:621-7. [Ref.ID 65461]
20. Cita con resumen
van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation. An individual patient meta-analysis. JAMA 2002;288:2441-8. [Ref.ID 64136]
Seleccionar todas
 
 1 a 20 de 39 siguiente >>